Salveen Richter

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) last week announced that the Phase 2 study of suzetrigine for painful lumbosacral radiculopathy (LSR) had met its primary endpoint. The company announced that the FDA had approved Alyftrek (or vanzacaftor triple) in cystic fibroris (CF) six years and older,...

Intellia Therapeutics Inc (NASDAQ: NTLA) is trading significantly higher Monday morning after the company announced positive clinical data for its CRISPR therapy. What Happened: Intellia and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) reported positive interim data from an ongoing Phase...

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) shares came under pressure Monday after the Food and Drug Administration (FDA) rejected its regulatory application seeking label expansion for its dementia drug. The Acadia Analysts: Goldman Sachs analyst Salveen Richter downgraded Acadia shares...

Moderna Inc (NASDAQ: MRNA) shares were trading at new highs Monday following the release of positive interim Phase 1 immunogenicity and safety data for its mRNA-1273 coronavirus vaccine candidate.  The Moderna Analysts Goldman Sachs analyst Salveen Richter maintained a Buy rating on Moderna...

Crispr Therapeutics AG (NASDAQ: CRSP) has surged 24 percent since the start of the year, but one analyst sees little more room to run. The Rating Goldman Sachs analyst Salveen Richter downgraded Crispr to Neutral and cut his price target from $78 to $40. The Thesis Richter considers Crispr a...

Intercept Pharmaceuticals Inc (NASDAQ: ICPT) reported top- and bottom-line beats last week that prompted two Street analysts to upgrade the stock. The Rating Goldman Sachs analyst Salveen Richter upgraded Intercept from Sell to Buy and more than tripled the price target from $46 to $157....

Madrigal Pharmaceuticals Inc (NASDAQ: MDGL), a clinical-stage biotechnology company, could spring a surprise in the non-alcoholic steatohepatitis, or NASH, space, according to Goldman Sachs.  The Analyst Analyst Salveen Richter initiated coverage of Madrigal with a Buy rating and...

Just weeks into its life as a publicly traded company, Solid Biosciences Inc (NASDAQ: SLDB) caught the eyes of four analysts who assumed coverage Tuesday with a mix of Holds and Buys. Here is what one of the more bearish critics had to say. The Rating Goldman Sachs analyst Salveen Richter...

2017 had a bullish tone, as assets across categories shone the brightest, although cryptocurrency could be singled out as the standout performer. Marijuana stocks also joined the party, as reflected by the 18.5-percent advance by the U.S. Marijuana Index. Momentum Extending Into The New Year...

Denali Therapeutics Inc. (NASDAQ: DNLI), a biotech company focusing on therapies for neurodegenerative disorders, IPO-ed in Dec. 2017, offering 13.9 million shares at $18 each.  The Analyst Goldman Sachs analyst Salveen Richter initiated coverage of Denali Therapeutics with a...

Goldman Sachs is downgrading Spark Therapeutics Inc (NASDAQ: ONCE) after the pharma startup presented disappointing data on its hemophilia A gene therapy at the annual meeting of the American Society of Hematology on Monday. The Analyst Goldman Sachs' Salveen Richter downgraded Spark...

Shares of cannabinoid-focused biotech company GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) are "on a path to new highs," according to Goldman Sachs. The Analyst Goldman Sachs analyst Salveen Richter upgraded GW Pharma from Neutral to Buy and lifted her price target to $174, suggesting...

Bluebird bio Inc (NASDAQ: BLUE)'s multiple myeloma therapy coud have a "disruptive impact" on treatment of the disease, according to Goldman Sachs. The Analyst Goldman Sachs' Salveen Richter maintains a Buy rating on bluebird's stock and raised the price target from $186 to...

The American Epilepsy Society (AES) annual meeting is scheduled to be held between December 2 and 6, during which GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH) will present on its lead anti-epilepsy drug Epidiolex, providing data from the first two positive Phase 3 studies. What To Expect The...